26 April 2019 2 Min Read
Vaccine sales give Sanofi shot in the arm in first quarter
Sanofi is counting on growth drivers such as the versatile Dupixent, which awaits approval in nasal polyps and is undergoing tests for lung disease, to replace ageing diabetes medicine Lantus
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In